Roche and Spark Therapeutics’ merger cleared by CMA
The CMA has cleared Roche and Spark Therapeutics' merger paving the way for the anticipated purchase of gene therapy company Spark Therapeutics by pharmaceutical...
Pfizer’s VYNDAQEL® (tafamidis) receives positive CHMP opinion
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of...
ABPI responds to General Election result
The ABPI has responded to the General Election result welcoming the news and saying that it is looking forward to working with the new...
Breast cancer blood test could help target treatment
A breast cancer blood test can help identify rare mutations in advanced breast cancer and may enable patients to access effective treatments more quickly...
Janssen presents initial results for BCMA CAR-T therapy
Janssen presents initial results for BCMA CAR-T therapy JNJ-4528 showing early, deep and high responses in the treatment of relapsed or refractory multiple myeloma. The...
Servier and UCL collaborate on immune-inflammatory disease treatments
Accelerating the discovery of new treatments for immune-inflammatory disease, including lupus and systemic sclerosis, is the focus of a new strategic research collaboration between...
Forendo and Novartis partner on novel chronic liver disease treatments
Forendo and Novartis are to partner on novel chronic liver disease treatments. Forendo Pharma, a clinical stage drug development company focusing on novel treatments...
Kite announces new Yescarta® data from pivotal ZUMA-1 trial
Kite announces new Yescarta® data from pivotal ZUMA-1 trial. The new data from the pivotal ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) showed that approximately...
AstraZeneca and MSD’s Lynparza™ now available in Scotland
AstraZeneca and MSD's Lynparza™ is now available in Scotland as the companies announce that olaparib monotherapy is now accepted for use by the Scottish...
Novartis highlights progress in R&D pipeline
Novartis is holding an investor event to provide a comprehensive overview of the company’s progress in advancing its R&D pipeline. Key highlights to be presented...
Latest articles
New community pharmacy quality standard highlights prevention role
A new community pharmacy quality standard published by NICE says that the teams have the potential to play a greater role in health promotion...
NICE wants more data on histology independent cancer treatments
The National Institute for Health and Care Excellence (NICE) is encouraging further data collection on ‘game changing’ histology independent cancer treatments. This comes as...
NICE approves Pfizer’s Ibrance in new combination for certain breast cancers
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following Pfizer's...
Popular articles
Nurofen launches a 24 hour ibuprofen pain relief patch
Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen. Despite body pain being among the most commonly...
Key publications to impact the UK access environment in 2020
Craig Bradley, Commercial Lead Rare GI at Takeda, PM Society Chair & PM Society Market Access Interest Group Lead, looks at key publications to...
NICE wants more data on histology independent cancer treatments
The National Institute for Health and Care Excellence (NICE) is encouraging further data collection on ‘game changing’ histology independent cancer treatments. This comes as...
Making a career move in pharma
If you feel that you have gone as far as you can in your current role, it could be time to make a career...
NICE approves Pfizer’s Ibrance in new combination for certain breast cancers
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following Pfizer's...